IDEAYA Biosciences enrolled the first patient in a Phase 1 clinical trial of IDE892, a novel PRMT5 inhibitor designed for patients with MTAP‑deleted solid tumors such as non‑small cell lung cancer and pancreatic cancer.
The study will assess safety, tolerability, pharmacokinetics and pharmacodynamics of IDE892 both as a monotherapy and in combination with IDE397, the company’s MAT2A inhibitor. Preclinical work has shown durable tumor regressions when PRMT5 and MAT2A are inhibited together, providing a strong scientific rationale for the combination approach.
This milestone de‑risks the IDE892 program and expands IDEAYA’s portfolio of targeted therapies for a genetically defined patient population. The company’s cash balance of approximately $1.05 billion as of December 31 2025 gives it a runway to 2030, while ongoing net losses are typical for a clinical‑stage biotech investing heavily in research and development.
Investors reacted positively to the announcement, reflecting confidence in the company’s strategy to focus on MTAP‑deleted and CDKN2A‑deficient tumors and its plan to advance combination therapies. Analysts have maintained buy ratings, underscoring the perceived value of the new clinical data.
IDEAYA plans to file an IND for its CDKN2A program in the first half of 2027 and will continue to evaluate the safety and early efficacy of IDE892 in the Phase 1 trial, with the goal of informing future development and potential regulatory submissions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.